Cargando…

High cyclin B1 expression is associated with poor survival in breast cancer

Cyclin B1 regulates the G(2)-M transition of the cell cycle. Cyclin B1 expression is higher in premalignant and malignant than normal breast lesions. Correlation of cyclin B1 expression with other histopathological variables and prognostic role in breast cancer are not fully understood. Traditionall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aaltonen, K, Amini, R-M, Heikkilä, P, Aittomäki, K, Tamminen, A, Nevanlinna, H, Blomqvist, C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669992/ https://www.ncbi.nlm.nih.gov/pubmed/19293801 http://dx.doi.org/10.1038/sj.bjc.6604874

Ejemplares similares

Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides
por: Aaltonen, K, et al.
Publicado: (2006)

Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families
por: Eerola, Hannaleena, et al.
Publicado: (2005)

Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families
por: Eerola, Hannaleena, et al.
Publicado: (2005)

The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome
por: Kumar, S R, et al.
Publicado: (2007)

Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer
por: Sun, S, et al.
Publicado: (2015)

Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells
por: Johnson, N, et al.
Publicado: (2010)

p53 mutation, deprivation and poor prognosis in primary breast cancer
por: Baker, L, et al.
Publicado: (2010)

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
por: Schwartz, G K, et al.
Publicado: (2011)

Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance
por: Kaliszczak, M, et al.
Publicado: (2013)

Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21
por: He, G, et al.
Publicado: (2006)

Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial–mesenchymal transition and poor overall survival
por: Kucia-Tran, Justyna A, et al.
Publicado: (2016)

HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer
por: Abdel-Fatah, T M A, et al.
Publicado: (2014)

The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer
por: Coley, H M, et al.
Publicado: (2012)

Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence
por: Pandya, K, et al.
Publicado: (2011)

RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses
por: Dolly, Saoirse O, et al.
Publicado: (2017)

Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families
por: Eerola, Hannaleena, et al.
Publicado: (2008)

Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases
por: Kim, S H, et al.
Publicado: (2008)

High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients
por: Bai, Tuya, et al.
Publicado: (2017)

An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer
por: Lee, H E, et al.
Publicado: (2011)

miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment
por: Piatopoulou, Despina, et al.
Publicado: (2017)

Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer
por: Hsu, K-F, et al.
Publicado: (2015)

Clinical importance of B7-H3 expression in human pancreatic cancer
por: Yamato, I, et al.
Publicado: (2009)

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
por: Fujita, T, et al.
Publicado: (2006)

Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration
por: Thomas, Z I, et al.
Publicado: (2011)

Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents
por: He, G, et al.
Publicado: (2013)

Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice
por: Ganai, S, et al.
Publicado: (2009)

Comprehensive analysis of NuMA variation in breast cancer
por: Kilpivaara, Outi, et al.
Publicado: (2008)

Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus
por: Makino, T, et al.
Publicado: (2009)

Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma
por: Nagata, M, et al.
Publicado: (2011)

OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy
por: Teft, W A, et al.
Publicado: (2015)

Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma
por: Campbell, L, et al.
Publicado: (2008)

GAMEC – a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours
por: Shamash, J, et al.
Publicado: (2007)

Aurora B expression modulates paclitaxel response in non-small cell lung cancer
por: Al-Khafaji, Ahmed SK, et al.
Publicado: (2017)

The endothelin B (ET(B)) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: potential for selective tumour blood flow modification
por: Cemazar, M, et al.
Publicado: (2005)

TP53 regulates human AlkB homologue 2 expression in glioma resistance to Photofrin-mediated photodynamic therapy
por: Lee, S Y, et al.
Publicado: (2010)

Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer
por: Smith, G, et al.
Publicado: (2012)

Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer
por: Seo, An Na, et al.
Publicado: (2016)

Plasticity and intratumoural heterogeneity of cell surface antigen expression in breast cancer
por: Remšík, Ján, et al.
Publicado: (2018)

Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells
por: Xu, Y, et al.
Publicado: (2009)

Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients' outcome
por: Charpin, C, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_34k4cj71kngj6stquuqia9upob